AMRI : Summary for Albany Molecular Research, Inc. - Yahoo Finance

U.S. Markets open in 2 hrs 50 mins

Albany Molecular Research, Inc. (AMRI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
16.39-2.22 (-11.93%)
At close: 4:00PM EST
People also watch
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
Previous Close18.61
Bid0.00 x
Ask16.87 x 8000
Day's Range15.60 - 17.58
52 Week Range12.45 - 19.35
Avg. Volume236,085
Market Cap681.51M
PE Ratio (TTM)-11.22
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents18 hours ago

    Edited Transcript of AMRI earnings conference call or presentation 21-Feb-17 1:30pm GMT

    Q4 2016 Albany Molecular Research Inc Earnings Call

  • Associated Press22 hours ago

    Albany Molecular Research posts 4Q loss

    Albany Molecular Research Inc. on Tuesday reported a fourth-quarter loss of $15.4 million, after reporting a profit in the same period a year earlier. On a per-share basis, the Albany, New York-based company ...

  • PR Newswire23 hours ago

    AMRI Announces Agreement with Accord Healthcare to Jointly Develop, Manufacture and Commercialize Parenteral Drug Products

    ALBANY, N.Y., Feb. 21, 2017 /PRNewswire/ -- AMRI (AMRI) today announced that it has entered into an agreement with the pharmaceutical group Ferrer  and Accord Healthcare, Inc. ("Accord Healthcare") to jointly develop and manufacture an undisclosed complex parenteral drug product for registration and subsequent commercialization in the United States with the option to partner on additional drug products. Under terms of the agreement, AMRI will work with Ferrer to develop and initially provide cGMP manufacturing and analytical support for the registration of the new product. Accord Healthcare will be responsible for advancing the product candidate through regulatory submission and commercialization.